NSTEMI Early Angiography Benefit Estimator Tool
Clinical assessment
Enter current clinical findings to support assessment of invasive angiography timing in adults with suspected NSTE-ACS.
Clinical context
This tool is intended for adults with suspected non-ST-elevation acute coronary syndrome (NSTE-ACS), when type 1 MI is part of the differential diagnosis. It organizes selected findings that may inform the timing of invasive coronary angiography. It does not establish the diagnosis of NSTEMI or replace bedside assessment.
Timing framework
| Clinical profile | Practical timing framework |
|---|---|
| Very high-risk instability | Immediate invasive assessment, as soon as possible (target within 2 hours when feasible). |
| High-risk timing features, such as GRACE >140, ongoing dynamic ST/T changes, or steeply rising biomarkers despite optimized treatment | Consider early angiography within 24 hours; integrate the full clinical picture and local pathways. |
| Stable patient without the above entered features | Confirm diagnosis and overall risk. If an invasive strategy is indicated, plan during the index admission; timing can be individualized. |
Important limitations
- Age ≥75 years, diabetes, and biomarker positivity may modify risk and the expected benefit of earlier intervention, but should not be used as stand-alone substitutes for full risk assessment.
- The original inputs do not include all guideline criteria, including transient ST elevation, confirmed NSTEMI using a validated high-sensitivity troponin algorithm, or all GRACE variables. Use clinical judgment and local ACS protocols.
- The tool does not estimate an individual probability of death, MI, or absolute benefit from early angiography.
- Bleeding risk, renal function, frailty, comorbidities, contraindications, coronary anatomy, patient preferences, and catheterization-laboratory availability must also be considered.
References
Rao SV, et al. J Am Coll Cardiol. 2025.
doi:10.1016/j.jacc.2024.11.009Byrne RA, et al. Eur Heart J. 2023;44:3720–3826.
doi:10.1093/eurheartj/ehad191TIMACS and VERDICT trials are discussed in the 2025 ACC/AHA guideline; the benefit of very early versus delayed angiography is not uniform across all-comers.
Guideline evidence reviewClinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.